TJPC(SH:600488)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥814,519,792.25, a decrease of 10.44% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 reached ¥28,343,847.98, an increase of 404.93% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥26,188,069.02, down 34.57% year-on-year[4]. - Basic earnings per share for Q3 2023 were ¥0.026, an increase of 388.89% compared to the same period last year[4]. - Total operating revenue for the first three quarters of 2023 reached CNY 2,837,778,648.87, an increase of 4.65% compared to CNY 2,711,794,040.59 in the same period of 2022[19]. - Net profit for the third quarter of 2023 was CNY 193,967,421.24, a significant increase of 264.5% compared to CNY 53,179,134.74 in the same quarter of 2022[20]. - The net profit attributable to shareholders of the parent company for the third quarter of 2023 was CNY 151,749,207.05, compared to CNY 51,532,561.70 in the same period last year[21]. - Basic and diluted earnings per share for the third quarter of 2023 were both CNY 0.139, up from CNY 0.047 in the same quarter of 2022[21]. - The company reported a total comprehensive income of CNY 201,518,626.09 for the third quarter of 2023, compared to CNY 65,275,009.86 in the same quarter of 2022[21]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥6,266,054,303.54, a decrease of 5.78% from the end of the previous year[5]. - The company's current assets totaled RMB 2,068,573,731.02, down from RMB 2,360,489,549.19 at the end of 2022, indicating a decrease of about 12.3%[15]. - The company's total liabilities decreased to RMB 1,876,102,686.55 from RMB 2,280,100,081.26, reflecting a decline of about 17.7%[16]. - The total liabilities decreased from CNY 2,896,862,345.04 in the previous year to CNY 2,347,577,845.34 in the current year[20]. - Total equity attributable to shareholders of the parent company increased to CNY 3,122,129,080.05 from CNY 2,972,508,434.31 year-on-year[20]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥465,386,680.37, an increase of 2.77%[4]. - The net cash flow from operating activities for the first nine months of 2023 was approximately ¥465.39 million, an increase from ¥452.86 million in the same period of 2022, reflecting a growth of about 2.3%[25]. - Total cash inflow from operating activities was approximately ¥2.62 billion, slightly down from ¥2.65 billion year-over-year[25]. - Cash outflow from operating activities totaled approximately ¥2.16 billion, compared to ¥2.20 billion in the previous year, indicating a decrease of about 1.8%[25]. - The net cash flow from investing activities was negative at approximately -¥89.94 million, compared to -¥138.44 million in the same period last year, showing an improvement[26]. - Cash inflow from financing activities was approximately ¥580.50 million, a significant decrease from ¥1.25 billion in the previous year[26]. - The net cash flow from financing activities was negative at approximately -¥540.29 million, contrasting with a positive net flow of ¥587.42 thousand in the same period last year[26]. - The total cash and cash equivalents at the end of the period stood at approximately ¥438.43 million, down from ¥535.04 million at the end of the previous year[26]. - The company received approximately ¥83.43 million in tax refunds, slightly up from ¥83.18 million year-over-year[25]. - The company reported a cash outflow of approximately ¥994.07 million for debt repayment, compared to ¥1.15 billion in the previous year, indicating a decrease of about 13.9%[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 44,172[9]. - The top shareholder, Tianjin Pharmaceutical Group Co., Ltd., holds 50.69% of the shares[9]. - The company repurchased and canceled a total of 2,310,000 shares due to unmet performance criteria for the restricted stock incentive plan, resulting in a total share count of 1,093,932,680 shares[11]. Research and Development - Research and development expenses for the first three quarters of 2023 were CNY 124,904,451.99, up from CNY 99,048,348.33 in the same period of 2022, indicating a focus on innovation[20]. - The product "Indacaterol Maleate" received approval for market entry in July 2023, which is expected to enhance the company's product portfolio and market reach[11]. - The company’s subsidiary achieved consistency evaluation for "Fluorouracil Injection," which is anticipated to improve market competitiveness and support future product evaluations[11]. - The company plans to enhance R&D efficiency and market expansion by managing 75.61% of Tianjin Pharmaceutical Research Institute's shares, aiming for high-quality development in the raw material and formulation sectors[12]. Government Support - The company received government subsidies amounting to ¥3,107,694.58 in Q3 2023, contributing to its financial performance[7].